A Phase 3 interventional study of HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate and gemcitabine; capecitabine in Pancreatic Cancer, sponsored by Fudan University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-01-22.
Sponsored by Fudan University · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 88 studies testing oxaliplatin in Pancreatic Neoplasms — 13 open to participants now, 19 under way, 7 of them phase 3. Oxaliplatin · Pancreatic Neoplasms.
Among the 88 studies testing oxaliplatin in Pancreatic Neoplasms, this one is the 2nd largest by planned enrollment of the 83 interventional ones that give a count, is one of 7 that started in 2024, is one of 14 in phase 3, reaches primary completion later than 10 of the 18 other live ones, and was the 82nd registered.
3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.
Browse Pancreatic Neoplasms studies →13 of the 88 studies testing oxaliplatin in Pancreatic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:
Hopital Foch · Sites in France
Ages 18–75
Dai, Guanghai · Sites in China
Ages 18–75
Du Juan · Sites in China
Ages 18+
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18+
Jiangsu HengRui Medicine Co., Ltd. · Sites in China
Ages 18–75
By country, each count listing its studies:
Oxaliplatin: first FDA approval 2002 (ELOXATIN). What it is approved for, and how studies give it, is on its page →
Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
88 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 57 · Phase 3 17 · Phase 4 1
First in 1998; this study’s year is marked. 7 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 524 is above the median of 47 across 2,936 interventional studies indexed under Pancreatic Neoplasms.
Median enrollment 46 across the 83 interventional studies. Of the 53 that completed or were terminated, 16 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 88 have an industry lead sponsor. The 10 most frequent:
Fudan University is the lead sponsor of 1,319 studies on the registry; 647 are open to participants now.
54 studies in Pancreatic Neoplasms by Fudan University: 27 open now, 28 under way, 6 of them phase 3. Of 7 finished, 0 (0%) have results posted.
Among the 54 studies in Pancreatic Neoplasms by Fudan University, this one is the 3rd largest by planned enrollment of the 48 interventional ones that give a count, is one of 14 that started in 2024, is one of 10 in phase 3, reaches primary completion later than 20 of the 27 other live ones, and was the 37th registered.
Fudan University’s Pancreatic Neoplasms studies by the year they started, since 2008.
4 of the studies testing oxaliplatin in Pancreatic Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04927780Phase 3Erasmus Medical CenterPerioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer | 2027-01 |
| NCT06217042Phase 3Fudan UniversityHR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer | 2027-03-30 |
| NCT06494514Du JuanNALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy as First-line Treatment of Locally Advanced Pancreatic Cancer | 2027-04-01 |
| NCT03977233UNC Lineberger Comprehensive Cancer CenterTumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer | 2027-07 |
Add all 4 to your calendar (.ics) → With an account.
Among the 88 studies testing oxaliplatin in Pancreatic Neoplasms, from their registry updates:
Among Fudan University’s 54 in Pancreatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to look at the efficacy and safety of HR070803 in combination with 5 fluorouracil/leucovorin (5FU/LV) plus oxaliplatin compared to gemcitabine + capecitabine treatment as adjuvant therapy in patients with resected pancreatic cancer.
STUDY DESIGN/ Evaluation criteria Main criterion: efficacy. The main criterion is the disease-free survival. Disease-free survival is defined as the time from date of randomization until the date of the first cancer-related event, second cancer, or death from any cause. Patients without event at the time of analysis will be censored at the date of last follow-up visit.
Secondary criteria include Overall survival. OS is defined as the time from date of randomization until the date of death from any cause. Patients who are still living at the time of analysis will be censored at the date of last follow-up visit.
Secondary criteria also include 3-year disease-free survival rate/overall survival rate and 5-year disease-free survival rate/overall survival rate.
Tolerance Patients evaluable for toxicity must have received one investigational drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate
Drug: HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate
gemcitabine; capecitabine
Drug: gemcitabine; capecitabine
Drug pages: Irinotecan Liposome HR070803Studies of Irinotecan Liposome HR070803Irinotecan Liposome HR070803 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · OxaliplatinStudies of OxaliplatinOxaliplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · FluorouracilStudies of FluorouracilFluorouracil pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · LeucovorinStudies of LeucovorinLeucovorin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Oxaliplatin 85 mg/m² D1 over 2 hours, followed by HR070803 60 mg/m² D1 over 90 minutes, after the Folinic acid infusion is started. Folinic acid 400 mg/m² D1, IV infusion over 1 hours. 5-FU 2400 mg/m² D1 IV continuous infusion over 46 hours. These drugs are given once every 2 weeks, 12 cycles, 24 weeks.
Drug pages: GemcitabineStudies of GemcitabineGemcitabine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · CapecitabineStudies of CapecitabineCapecitabine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Gemcitabine 1000mg/m² is given as an i.v. infusion over 30 minutes, administered on day 1, 8 and 15 out of 28 days. Capecitabine 1660mg/m²/day in two divided doses administered orally for 21 days followed by 7 days'rest .
Disease-free survival (DFS)
Disease-free survival is defined as the time from date of randomization until the date of the first cancer-related event, second cancer, or death from any cause.
Time frame: From study start until 338 DFS events have occurred (approximately 21 months after last patient enrollment)
Overall survival (OS)
OS is defined as the time from date of randomization until the date of death from any cause.
Time frame: From date of randomization until the date of death from any cause, assessed up to 37 months
3-year disease-free survival rate
Disease-free survival within 3 years
Time frame: up to 36 months following the date the first patient was randomized
5-year disease-free survival rate
Disease-free survival within 5 years
Time frame: up to 60 months following the date the first patient was randomized
3-year overall survival rate
Overall survival within 3 years
Time frame: up to 36 months following the date the first patient was randomized
5-year overall survival rate
Overall survival within 5 years
Time frame: up to 60 months following the date the first patient was randomized
Plan to share: Yes — study protocol and ICF, CSR will be shared.
Supporting information: Study protocol, Informed consent form, Clinical study report
Time frame: Ending of trials, preserved for 10 years.
Access criteria: Researchers within pancreatic cancer field.
No publications or documents are linked to this record.
Start is estimated for Feb 2024; primary completion for Mar 2027, 37 months later.
Of 46 non-industry phase 3 interventional studies under Pancreatic Neoplasms, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 79. This study's planned 37 months is below that.
Counting every sponsor, half of 84 studies reached it within 60 months; a quarter within 36 and three quarters within 77.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Irinotecan Liposome HR070803 · Oxaliplatin · Fluorouracil · Leucovorin